15% OFF $150+· CodeFALL15
Ends October 15Shop now
Lot certificates published
Discreet shipping

Compound monograph

HNGF6A

HNGF6A is a synthetic humanin analog with F6A and S14G substitutions, described as non-IGFBP-3-binding in a comparative disposition study.

Published: 2026-09-16Literature/identifier verification: 2026-09-15
HNGF6AF6A/S14G-humaninMitochondrial-derived peptides

01

Identity & nomenclature

HNGF6A is a synthetic humanin analog with F6A and S14G substitutions, described as non-IGFBP-3-binding in a comparative disposition study.

HNGF6A is not an alias of humanin or HNG. F6A-humanin alone is a third molecule again — it retains Ser14. Some records collapse humanin and its derivatives under broad substance names, so the sequence must control assignment rather than the label.

Canonical name: [Ala6,Gly14]-humanin.

Declared aliases and development codes: HNGF6A, F6A/S14G-humanin.

02

Molecular properties

Molecular formulaC112H198N34O31S2
Molecular mass2581.1 Da
CAS Registry Number1093111-54-6
PubChem CID90489015
One-letter sequenceMAPRGASCLLLLTGEIDLPVKRRA

Twenty-four residues, free at both termini. Two substitutions relative to humanin: F6A and S14G. Chain length is unchanged, so '24-residue humanin analog' does not identify it.

03

Structural characteristics

A rodent study compared HNGF6A with HNG in wild-type animals and HNG in animals lacking IGFBP-3. Its non-IGFBP-3-binding designation defines the comparison; plasma humanin immunoreactivity does not establish intact-peptide identity. A separate study explicitly examined HNGF6A in isolated islets and cultured murine beta cells with scrambled-peptide controls and assessed K-ATP channel dependence. Those experimental systems do not establish a direct receptor assignment for this double-substituted peptide.

  • F6A
  • S14G

Terminal features: Free N-terminus, Free C-terminal carboxyl.

04

Molecular targets & mechanisms

05

Analytical considerations

Require fragments establishing BOTH Ala6 and Gly14; either alone leaves it indistinguishable from HNG or from F6A-humanin. Relative to HNG the F6A substitution removes C6H4, a calculated monoisotopic difference of 76.031 Da. Testing IGFBP-3 binding characterises function and cannot substitute for chemical identity — degradation, aggregation or assay failure would all produce an apparent absence of binding.

06

Verified bibliography

  1. Pharmacokinetics and tissue distribution of humanin and its analogues in male rodents.

    Chin YP, Keni J, Wan J, Mehta H, Anene F, Jia Y, Lue YH, Swerdloff R, Cobb LJ, Wang C, Cohen P

    Endocrinology · 2013-07-08 · Journal Article

    current
  2. Potent humanin analog increases glucose-stimulated insulin secretion through enhanced metabolism in the β cell.

    Kuliawat R, Klein L, Gong Z, Nicoletta-Gentile M, Nemkal A, Cui L, Bastie C, Su K, Huffman D, Surana M, Barzilai N, Fleischer N, Muzumdar R

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2013-08-30 · Journal Article

    current

10

Methodology & citation verification

Reference identity is checked against official PubMed metadata. Local deterministic receipts bind each normalized title and canonical metadata record to its verification date. Scientific values remain absent when an authoritative source has not been verified.

Read the full methodology →